高级检索
当前位置: 首页 > 详情页

Inhibition viral RNP and anti-inflammatory activity of coumarins against influenza virus

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 PR China [2]Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510405 PR China [3]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510006 PR China [4]State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China
出处:
ISSN:

关键词: Coumarins Eleutheroside B-1 Influenza virus Viral ribonucleoprotein Anti-inflammatory

摘要:
Influenza viruses pose a severe threat to human health and a significant increase in antiviral drug-resistant among influenza viruses worldwide has been observed. Therefore, there is an urgent need to develop the new antiviral drugs, specifically from the natural products. In this study, the anti-viral and anti-inflammatory activities of coumarins against influenza A virus in vitro were investigated. One of the derivatives eleutheroside B-1 showed a wide spectrum of anti-human influenza virus effect with the IC50 value of 64-125 mu g/ml in vitro, but it showed no effects against avian influenza virus. The time of addition was done and the results indicated that it had a potent antiviral effect when added at 0-6 h, and also the virus yield was reduced by 60%. The influenza virus ribonucleoprotein was inhibited at 200 mu g/ml, and also the NP mRNA expression was inhibited at 50 and 200 mu g/ml. The expression level of cytokines and chemokines influenced by eleutheroside B-1 was further demonstrated, the IL-6, CXCL-8, CCL-2 expression were all inhibited by the eleuthe roside B-1 at concentration 200 mu g/ml. The findings of study suggest that eleutheroside B-1 can be as potential agent to develop for the prevention and treatment of influenza A virus. (C) 2016 Elsevier Masson SAS. All rights reserved.

基金:

基金编号: development

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 3 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 2 区 药学
JCR分区:
出版当年[2015]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 PR China
共同第一作者:
通讯作者:
通讯机构: [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 PR China [3]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510006 PR China [4]State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China [*1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, PR China. [*2]Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China. [*3]State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号